Compare NMI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NMI | ACOG |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.9M | 129.4M |
| IPO Year | N/A | N/A |
| Metric | NMI | ACOG |
|---|---|---|
| Price | $10.18 | $4.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 28.4K | ★ 74.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $3.75 |
| 52 Week High | $10.05 | $11.54 |
| Indicator | NMI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 49.64 |
| Support Level | $10.06 | $4.75 |
| Resistance Level | $10.25 | $5.99 |
| Average True Range (ATR) | 0.11 | 0.58 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 79.07 | 63.36 |
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.